CT-95 (mesothelin)

August 5, 2026: Context Therapeutics (NASDAQ: CNTX) said it is prioritizing CTIM-76 and CT-202 and discontinuing CT-95 (MSLN x CD3) as part of a portfolio and capital allocation strategy.

CTIM-76 (CLDN6 x CD3), in Phase 1 monotherapy for platinum-resistant ovarian cancer (PROC): the company reported interim Phase 1a weekly-dosing safety, tolerability, and efficacy data in June 2026 in a limited number of heavily pretreated patients, which management described as encouraging. The FDA granted Fast Track designation in April 2026 for PROC after all standard-of-care therapies. Context plans to evaluate every-three-week dosing in less heavily pretreated PROC patients in 2H 2026. Upcoming milestones are Phase 1b dose expansion initiation in Q1 2027 and initial Phase 1a Q3W safety, tolerability, and efficacy data in Q2 2027.

CT-202 (Nectin-4 x CD3), in Phase 1 monotherapy for urothelial, colorectal, and triple-negative breast cancers: the program received Human Research Ethics Committee approval and Australian TGA Clinical Trial Notification acknowledgement in April 2026 for a first-in-human Phase 1 trial. In May 2026, Context amended its BioAtla license agreement to remove future milestones and royalty obligations. First patient dosing is expected in 3Q 2026, with initial Phase 1a topline safety, tolerability, and early efficacy data expected in 2H 2027.

Cash was $43.0 million as of June 30, 2026, with runway projected into Q4 2027.